RT Journal Article SR Electronic T1 A High Serum Uric Acid Level Is Associated with Poor Prognosis in Patients with Acute Myeloid Leukemia JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 3947 OP 3951 VO 33 IS 9 A1 TAKAHIRO YAMAUCHI A1 EIJU NEGORO A1 SHIN LEE A1 MIHOKO TAKAI A1 YASUFUMI MATSUDA A1 KAZUTAKA TAKAGI A1 SHINJI KISHI A1 KATSUNORI TAI A1 NAOKO HOSONO A1 TOSHIKI TASAKI A1 SATOSHI IKEGAYA A1 KUNIHIRO INAI A1 AKIRA YOSHIDA A1 YOSHIMASA URASAKI A1 HIROMICHI IWASAKI A1 TAKANORI UEDA YR 2013 UL http://ar.iiarjournals.org/content/33/9/3947.abstract AB Uric acid in serum (S-UA) is produced by the breakdown of the cellular nucleic acids of leukemia cells, and may be a marker of disease aggressiveness. S-UA levels were examined for association with clinical outcomes in patients with acute myeloid leukemia (AML). Fifty-six patients with AML admitted to our Institution were evaluated retrospectively. The median S-UA level at diagnosis was 5.0 mg/dl (range 2-13.8 mg/dl). The S-UA levels did not correlate with peripheral lactate dehydrogenase, peripheral white blood cell counts, or peripheral blast counts, and were not proportional to bone marrow blast counts or marrow cellularity. The S-UA levels in the patients who achieved complete remission were slightly lower than those in those who did not. S-UA levels less than, or equal to the median (5.0 mg/dl) were significantly associated with better prognoses, compared with S-UA levels greater than 5.0 mg/dl. Thus, the S-UA level may predict the prognosis of AML, and is a versatile and cost-effective test for such a purpose.